As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Gauduin, Marie-Claire E.
Funded by
NIH-PMS
There is currently no efficient vaccine developed to prevent infection by the Human Immunodeficiency Virus (HIV), the agent responsible for Acquired Immunodeficiency Syndrome (AIDS). Classic vaccine strategies, such as the use of live attenuated viruses, where the immune system is stimulated by exposure of the host organism to non infectious viral particles, have led to safety issues in the case of HIV. We propose to develop a new vaccine strategy that elicits a long-term immunity against HIV infection at the site of entry of the virus in the case of mucosal infection.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Cole, Shelley A.
Funded by
Johns Hopkins Univ.Bloomberg School of PH
The goal of this project is to evaluate the role of DNA epigenetic modifications and their role in mediating the association between arsenic exposure and CVD in participants of the Strong Heart Study (SHS).
The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.
Principal Investigator(s)
Kadosh, David
Funded by
NIH
Candidiasis represents the third leading cause of hospital-acquired bloodstream infections in the U.S. Candida albicans, the most commonly isolated human fungal pathogen, is associated with 50% of infections while several non-albicans Candida species (NACS), including Candida tropicalis and Candida parapsilosis, account for the remainder of cases. Only three major classes of antifungals are currently available for treatment and there is a significant demand for new and more effective therapies. A major virulence property of C.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Anderson, Timothy J. C.
Funded by
UTHSCSA
The goal is to identify and characterize novel anti-schistosomal drugs to treat this disease.
The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.
Principal Investigator(s)
Doyle, Allison
Funded by
NIH
Peripherally acting opioids are desirable for producing analgesia while eliminating debilitating central side effects, such as tolerance, dependence and addiction. However, peripheral opioid efficacy is significantly reduced in the absence of tissue inflammation. The long-term goal of this research project is to understand how inflammation enhances peripheral opioid efficacy. For example, in the absence of inflammation the delta opioid receptor (DOR) is less responsive to agonist activation.